Dyadic International, Inc. (DYAI)
| Market Cap | 17.06M -57.1% |
| Revenue (ttm) | 3.80M -8.0% |
| Net Income | -7.62M |
| EPS | -0.21 |
| Shares Out | 36.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 53,961 |
| Open | 0.4400 |
| Previous Close | 0.4650 |
| Day's Range | 0.4351 - 0.4700 |
| 52-Week Range | 0.3401 - 1.6000 |
| Beta | 0.96 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 11, 2026 |
About DYAI
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research a... [Read more]
Financial Performance
In 2025, Dyadic International's revenue was $3.09 million, a decrease of -11.59% compared to the previous year's $3.50 million. Losses were -$7.36 million, 26.8% more than in 2024.
Financial StatementsNews
Dyadic International Transcript: IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026
Transitioning from R&D to commercial execution, multiple products are now on the market across life sciences, food, and bioindustrial sectors, supported by diverse revenue models and strategic partnerships. Near-term growth is expected from life sciences, with a significant sales ramp anticipated by early 2027.
Dyadic International files to sell 3.625M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 3.625M shares of common stock. The company is not selling any…
Dyadic International Registration statement: Registration filing
Dyadic International filed a registration statement on September 11, 2026, providing details about a securities offering with the SEC.
Dyadic International Transcript: Q3 Investor Summit Group Virtual Conference 2026
Transitioned from R&D to commercial stage, launching multiple non-animal protein products across life sciences, food, and bioindustrial markets. Leveraging a differentiated gene expression platform, the company is generating initial revenues, expanding partnerships, and targeting cash flow positivity through recurring sales and strategic collaborations.
Dyadic International prices 3.625M shares at 79.5c in registered direct offering
Dyadic International (DYAI) announced definitive agreements with an institutional investor for the purchase and sale of shares of Common Stock in a registered direct offering with a concurrent private...
Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement
JUPITER, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ: DYAI) (the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein so...
Dyadic International Earnings Call Transcript: Q2 2026
Q2 2026 marked a shift toward commercial operations, with initial product sales, expanded partnerships, and improved manufacturing economics. Revenue was flat year-over-year, but six-month revenue rose 52%. Liquidity concerns persist, but multiple financing and non-dilutive funding options are being pursued.
Dyadic International Earnings release: Q2 2026
Dyadic International released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Dyadic International Quarterly report: Q2 2026
Dyadic International has published its Q2 2026 quarterly earnings report on August 12, 2026.
Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas
JUPITER, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology co...
Dyadic enters commercial license agreement with European biotechnology company
Dyadic International (DYAI) announced the expansion of its commercial non-animal dairy pipeline through a new development and commercial license agreement with a European biotechnology company for add...
Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement
JUPITER, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinan...
Dyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026
JUPITER, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology com...
Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days
JUPITER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, today announced that, within approximately 15...
Dyadic International regains compliance with Nasdaq
Dyadic International (DYAI) announced that Nasdaq has confirmed that the company has regained compliance with Nasdaq Listing Rules 5550 and 5550. The company’s common stock continues to be listed and…
Dyadic Announces Continued Listing on the Nasdaq Capital Market
JUPITER, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinan...
Dyadic expands bio-industrial pipeline with new industrial enzyme program
Dyadic International (DYAI) announced the expansion of its bio-industrial pipeline with a new proprietary industrial enzyme program focused on advanced cellulose processing. “We see this program as a ...
Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program
JUPITER, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinan...
Global Collaborations Continue to Validate Dyadic's C1 Platform and Expands Commercial Potential
Global Collaborations Continue to Validate Dyadic's C1 Platform and Expand Commercial Opportunity Dyadic's Ebola preparedness work highlights C1's potentia
Dyadic International Slides: Corporate presentation
Dyadic International has posted slides in relation to its latest quarterly earnings report, which was published on June 30, 2026.
Dyadic International allowed claims by Japan Patent Office
Dyadic International (DYAI) announced that the Japan Patent Office has allowed claims covering its proprietary Thermothelomyces heterothallica recombinant protein expression technology. The Japan Pate...
Dyadic Expands IP Protection and Business Development Activities in Japan
JUPITER, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the develo...
An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets
SmallCaps Daily Sits Down with Joe Hazelton to Discuss Dyadic's Product Strategy, Strategic Partnerships, and Long-Term Growth Vision New York, New York--(Newsfile Corp. - June 22, 2026) - Dyadic Appl...
Dyadic International Transcript: AGM 2026
The meeting covered approval of all shareholder proposals, including a reverse stock split and director election. Strategic updates highlighted commercial growth, new partnerships, and ongoing Nasdaq compliance efforts. Shareholders were invited to participate in a Q&A session.
Dyadic International Proxy statement: Proxy filing
Dyadic International filed a proxy statement on June 18, 2026, providing details for shareholder voting and corporate governance matters.